A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
Ontology highlight
ABSTRACT: This is a Phase I, open-label, multi-centre, drug combination study of double and triple combination oral selumetinib (AZD6244 Hyd-sulfate) plus intravenous (IV) MEDI4736 and oral selumetinib plus IV MEDI4736 and IV tremelimumab in patients with advanced solid tumours.
DISEASE(S): Head And Neck Carcinoma,Lung Cancer,Pancreatic Adenocarcinoma,Biliary Tract Cancer,Biliary Tract Neoplasms,Melanoma,Colorectal Cancer,Gastroesophageal Cancer,Breast Cancer
PROVIDER: 2200961 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA